Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002
Not Yet Recruiting
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for Post Traumatic Stress Disorder (PTSD) utilizing an adaptive platform trial (APT) design. Intervention D - SLS-002 will assess the safety and efficacy of SLS-002 in participants with PTSD. Please see NCT05422612 for information on the S-21-02 Master Protocol.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/06/2025
Locations: Advanced Discovery Research, Atlanta, Georgia
Conditions: Post Traumatic Stress Disorder
Morphine or Ketamine for Analgesia
Not Yet Recruiting
Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration. The investigators aim to determine if sub-dissociative ketamine is non-inferior to morphine for treating acute pain and a preferable alternative... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/17/2025
Locations: Arthur M. Blank Hospital, Atlanta, Georgia
Conditions: Abdominal Pain, Isolated Extremity Fracture, Pain, Pediatrics
A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health
Completed
Ketamine-Assisted Psychotherapy (KAP) is a relatively new approach for the treatment of mental health issues, which involves the combination of ketamine, a dissociative anaesthetic with psychedelic properties, and psychotherapy to promote emotional wellbeing. In this study, we investigated the effectiveness of KAP in adult patients coping with mental health. We predicted that clients would experience lasting reductions in psychological distress over time, such as depression, anxiety, and post tr... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
02/22/2024
Locations: Atlanta Centre, Atlanta, Georgia
Conditions: Depression, Anxiety, Post Traumatic Stress Disorder
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
Completed
The purpose of the study is to evaluate the efficacy, safety, and tolerability of SLS-002 (intranasal racemic ketamine) in addition to standard of care on symptoms of Major Depressive Disorder (MDD) and suicidality, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/25/2023
Locations: Seelos Investigational Site, Atlanta, Georgia +1 locations
Conditions: Depressive Disorder, Major, Suicidal
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
Completed
This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study was conducted in the US and in Europe (Spain). The MIJ821 was administered via infusion on a weekly or bi-weekly basis. The efficacy was measured after 24 hours using a specific golden standard scale, the Montgomery-Asberg Depression Rating Scale. The study duration was 6 weeks of treatment plus 1 month of follow up... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/07/2021
Locations: Novartis Investigative Site, Atlanta, Georgia
Conditions: Depressive Disorder, Treatment-Resistant
Intranasal (NAS) Ketamine for Cancer Pain
Completed
The main purpose of this study is to determine the safety, feasibility, and utility of intranasal (NAS) ketamine in persistent uncontrolled cancer related pain. In this prospective clinical trial the researchers will investigate the use of NAS ketamine in patients with pain related to cancer or cancer treatment. The researchers plan to enroll at least 25 patients meeting inclusion/exclusion criteria, to achieve a minimum of 10 patients who complete the study. Participants will be recruited from... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2021
Locations: Winship Cancer Institute, Atlanta, Georgia
Conditions: Cancer, Pain
Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients
Terminated
The goal of this prospective randomized double blinded placebo controlled study is to investigate if a single dose of ketamine in addition to standard anesthesia will reduce the risk of delirium in otolaryngeal cancer patients postoperatively. Ketamine's effect on post-operative pain and opioid use will be measured as well. Electroencephalogram (EEG) will be utilized during the surgical procedure to evaluate its potential as a possible predictive device for delirium.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2021
Locations: Emory University Hospital Midtown, Atlanta, Georgia
Conditions: Otolaryngeal Cancer
Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery
Completed
The purpose of this research study is to evaluate the safety and analgesic efficacy of PMI-150 (intranasal ketamine) compared to placebo in patients with acute post-operative pain following orthopedic trauma, injury, or surgery.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/10/2012
Locations: Southeastern Center for Clinical Research, Atlanta, Georgia
Conditions: Pain, Postoperative